Brief: Radiopharm Theranostics Announces 50% Enrollment In Phase 2B Clinical Trial Of Rad101 Imaging In Brain Metastases
17/11/2025 13:11
Radiopharm Theranostics Ltd RAD.AX: RADIOPHARM THERANOSTICS ANNOUNCES 50% ENROLLMENT IN PHASE 2B CLINICAL TRIAL OF RAD101 IMAGING IN BRAIN METASTASES RADIOPHARM THERANOSTICS LTD - PHASE 2B TRIAL TO COMPLETE ENROLLMENT AND HAVE TOPLINE DATA IN 1H26 Source text: ID:nGNX2bPzpf Further company coverage: RAD.AX
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%